Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma

• Главные авторы: Xiaoming Bai (Автор), Dan Xiang (Автор), Mengxi Huang (Автор), Yitian Chen (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

FH-deficient Renal Cell Carcinoma (FH-deficient RCC) are inherited tumors caused by mutations in the fumarate hydratase (FH) gene, which plays a role in the tricarboxylic acid cycle. These mutations often result in aggressive forms of renal cell carcinoma (RCC) and other tumors. Here, we present a c...